Anti-EGF antibody (ab9695)
Key features and details
- Rabbit polyclonal to EGF
- Suitable for: WB, IHC-P, ELISA, Neutralising, Sandwich ELISA
- Reacts with: Human, Recombinant fragment
- Isotype: IgG
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-EGF antibody
See all EGF primary antibodies -
Description
Rabbit polyclonal to EGF -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-P, ELISA, Neutralising, Sandwich ELISAmore details -
Species reactivity
Reacts with: Human, Recombinant fragment -
Immunogen
Recombinant full length protein corresponding to Human EGF. Highly pure (>98%) recombinant hEGF (human Epidermal Growth Factor)
Database link: P01133 -
Positive control
-
General notes
Although some customers have been successful in IHC we no longer batch test in this application. For IHC validate antibody please see ab184265.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Lyophilized:Reconstitute with 200µl of sterile water. -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. -
Storage buffer
No preservative, sterile filtered -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Light chain type
unknown -
Research areas
Associated products
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab9695 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (2) |
Use a concentration of 0.1 - 0.2 µg/ml. To detect hEGF by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hEGF is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. Western blot bands should be around 6.2 kDa.
|
IHC-P | (1) |
Use at an assay dependent concentration.
|
ELISA |
Use at an assay dependent concentration.
To detect hEGF by direct ELISA (using 100µl/well antibody solution) a concentration of at least 0.5µg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant hEGF. |
|
Neutralising |
Use at an assay dependent concentration.
To yield one-half maximal inhibition [ND50] of the biological activity of hEGF (2.0 ng/ml), a concentration of 0.25 - 0.35 µg/ml of this antibody is required. |
|
Sandwich ELISA |
Use a concentration of 0.5 - 2 µg/ml.
For sandwich ELISA, use this antibody as Detection at 0.5µg/ml with ab18635 as Capture. |
Notes |
---|
WB
Use a concentration of 0.1 - 0.2 µg/ml. To detect hEGF by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hEGF is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions. Western blot bands should be around 6.2 kDa. |
IHC-P
Use at an assay dependent concentration. |
ELISA
Use at an assay dependent concentration. To detect hEGF by direct ELISA (using 100µl/well antibody solution) a concentration of at least 0.5µg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of 0.2 - 0.4 ng/well of recombinant hEGF. |
Neutralising
Use at an assay dependent concentration. To yield one-half maximal inhibition [ND50] of the biological activity of hEGF (2.0 ng/ml), a concentration of 0.25 - 0.35 µg/ml of this antibody is required. |
Sandwich ELISA
Use a concentration of 0.5 - 2 µg/ml. For sandwich ELISA, use this antibody as Detection at 0.5µg/ml with ab18635 as Capture. |
Target
-
Function
EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. Can induce neurite outgrowth in motoneurons of the pond snail Lymnaea stagnalis in vitro (PubMed:10964941). -
Tissue specificity
Expressed in kidney, salivary gland, cerebrum and prostate. -
Involvement in disease
Hypomagnesemia 4 -
Sequence similarities
Contains 9 EGF-like domains.
Contains 9 LDL-receptor class B repeats. -
Post-translational
modificationsO-glycosylated with core 1-like and core 2-like glycans. It is uncertain if Ser-954 or Thr-955 is O-glycosylated. The modification here shows glycan heterogeneity: HexHexNAc (major) and Hex2HexNAc2 (minor). -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 1950 Human
- Omim: 131530 Human
- SwissProt: P01133 Human
- Unigene: 419815 Human
-
Alternative names
- Beta urogastrone antibody
- beta-urogastrone antibody
- EGF antibody
see all
Images
-
Primary ab9695 was used at a dilution of 0.2 ug/ml.
Lane 1: 250 ng Recombinant human EGF protein
Lane 2: 125 ng Recombinant human EGF protein
Datasheets and documents
-
SDS download
-
Datasheet download
References (31)
ab9695 has been referenced in 31 publications.
- Valente WAS et al. Expression of epithelial growth factors and of apoptosis-regulating proteins, and presence of CD57+ cells in the development of inflammatory periapical lesions. J Appl Oral Sci 30:e20210413 (2022). PubMed: 35195153
- Park JY et al. The Potential of Transforming Growth Factor-beta Inhibitor and Vascular Endothelial Growth Factor Inhibitor as Therapeutic Agents for Uterine Leiomyoma. Int J Med Sci 19:1779-1786 (2022). PubMed: 36313223
- Ma M et al. SMAD-specific E3 ubiquitin ligase 2 promotes angiogenesis by facilitating PTX3 degradation in MSCs from patients with ankylosing spondylitis. Stem Cells 39:581-599 (2021). PubMed: 33547700
- Wu M et al. P25 Gene Knockout Contributes to Human Epidermal Growth Factor Production in Transgenic Silkworms. Int J Mol Sci 22:N/A (2021). PubMed: 33800168
- Liang J et al. The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis. Br J Cancer 125:390-401 (2021). PubMed: 34088989